Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
Status: | Terminated |
---|---|
Conditions: | Parkinsons Disease, Infectious Disease, Gastrointestinal |
Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases, Neurology |
Healthy: | No |
Age Range: | Any |
Updated: | 12/3/2017 |
Start Date: | January 2008 |
End Date: | June 2012 |
Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease
The purpose of this study is to determine whether treatment of H. pylori (an infection of the
stomach) improves treatment effectiveness in patients with Parkinson's disease and motor
fluctuations.
stomach) improves treatment effectiveness in patients with Parkinson's disease and motor
fluctuations.
Previous investigations have demonstrated that treatment of Helicobacter pylori with
antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may
potentially benefit patients with Parkinson's disease who have motor fluctuations,
specifically excessive "off" time, when their levodopa is not working to control symptoms. We
seek to identify the frequency of H. pylori infection in this population using standard lab
assays and determine whether eradication with standard triple therapy results in improved
clinical response to medication.
antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may
potentially benefit patients with Parkinson's disease who have motor fluctuations,
specifically excessive "off" time, when their levodopa is not working to control symptoms. We
seek to identify the frequency of H. pylori infection in this population using standard lab
assays and determine whether eradication with standard triple therapy results in improved
clinical response to medication.
Inclusion criteria:
- Adults diagnosed with idiopathic Parkinson's disease, Hoehn & Yahr stage 2-4 in the
"off" state, with no other concomitant neurologic diseases.
- Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy,
but with wearing off phenomenon present between levodopa doses (average off time ≥3
hours off time/day).
- Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is
acceptable. Parkinson's disease treatment may also include any of the following
medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B
inhibitors, amantadine, anticholinergics.
- Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment
arms).
Exclusion criteria:
- Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.
- History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal
lesions.
- History of previous gastric surgery.
- History of previous brain surgery for Parkinson's disease.
- Family history of gastric cancer.
- Prior treatment for H. pylori+ status.
- Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or
clarithromycin.
- Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.
- Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).
- Inability to tolerate or participate in testing in the morning in an "off" state.
- Inability to communicate effectively with study personnel in English.
- Pregnancy.
We found this trial at
1
site
Click here to add this to my saved trials